Skip to main content
logo
Esperion Therapeutics, Inc. (ESPR)
Jul 13, 2026 - ESPR was delisted
3.180
-0.010 (-0.31%)
Inactive · Last trade price on Jul 10, 2026

Esperion Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
418.24403.14332.31116.3375.4878.45
Revenue Growth
61.13%21.31%185.66%54.14%-3.79%-65.53%
Gross Profit
241.7226.06217.48-13.04-70.42-41.75
Operating Income
75.7960.2754.4-155.56-179.5-213.48
Net Income
-7.42-22.68-51.75-209.25-233.66-269.11
Earnings Per Share
-0.03-0.11-0.28-2.03-3.52-9.31
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
156.16167.85144.7682.25166.86259.33
Total Debt
543.81548591.21540.95504.55517.24
Net Cash (Debt)
-387.65-380.15-446.45-458.7-337.69-257.9
Net Cash Growth
------
Net Cash Per Share
-1.75-1.83-2.39-4.45-5.09-8.92

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-18.19-13.09-23.65-135.49-174.83-263.81
Capital Expenditures
-0.19--0.32---
Free Cash Flow
-18.38-13.09-23.97-135.49-174.83-263.81
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
57.79%56.07%65.44%-11.21%-93.30%-53.21%
Operating Margin
18.12%14.95%16.37%-133.72%-237.83%-272.13%
Pretax Margin
-1.33%-5.17%-15.57%-179.87%-309.58%-343.04%
Profit Margin
-1.77%-5.63%-15.57%-179.87%-309.58%-343.04%
FCF Margin
-4.39%-3.25%-7.21%-116.46%-231.64%-336.29%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-12.2616.60---
PS Ratio
1.962.161.302.926.083.90